3. • A recombinant humanized
monoclonal antibody
• against human epidermal
growth receptor 2 protein
(HER2)
4. Use
• Approved to be used alone or with
other drugs to treat:
• Adenocarcinoma of stomach or gastro
esophageal junction.
• used for HER2 positive(HER2+) disease that
has metastasized (spread to other parts of the
body) in patients who have not already been
treated for metastatic cancer.
• Breast cancer that is HER2+.
5. • HER2 overexpressed by many adenocarcinomas,
particularly breast adenocarcinomas
• Overexpression of the HER2 protein, amplification
of the HER2 gene, or both, occur in approximately
15-25% of breast cancers
• associated with aggressive behaviour in the
tumour
6. • for women with breast cancer who have
an overexpression of HER2
• herceptin might be useful as adjuvant
therapy (before/after/in combination) with
established other chemotherapeutic
agents
• (eg anthracyclines and taxanes), surgery
and radiation treatment.
7. • has survival benefit when given with
chemotherapy to patients
• with early, operable, and metastatic breast
cancer that has HER2 overexpression or
amplification
8. Mode of action
• After binding to HER2 on the tumor cell
surface, trastuzumab induces an antibody-
dependent cell-mediated cytotoxicity
against tumor cells that overexpress HER2
9. Trastuzumab mediates ADCCOnce bound to the Fc
domain of trastuzumab,
the NK cellsrelease
substances…
that perforatethe
tumour cellmembrane
and promote celldeath
11. Fig 3: Journal of the New Zealand Medical
Association, 02-June-2006, Vol 119 No 1235
12. Side effects
• diarrhea
• constipation
• heartburn
• loss of appetite
• back, bone, joint, or muscle pain
• difficulty falling asleep or staying asleep
• numbness, burning, or tingling in the arms,
hands, feet, or legs
• changes in the appearance of nails
13. Serious side effects
• Cardiac failure
• sore throat, fever, chills, difficulty
urinating, pain when urinating, and
other signs of infection
• nosebleeds and other unusual
bruising or bleeding
• excessive tiredness
• pale skin